PRESS RELEASES More events are coming soon. Keyword Search Year: 201820172016201520142013 12/04/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 12/03/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 11/29/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 11/19/18 Summary ToggleTRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting Printer Friendly PDF Version 11/15/18 Summary ToggleTRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma Printer Friendly PDF Version 11/07/18 Summary ToggleTRACON Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Printer Friendly PDF Version 10/31/18 Summary ToggleTRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018 Printer Friendly PDF Version 09/10/18 Summary ToggleTRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC Printer Friendly PDF Version 08/29/18 Summary ToggleTRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference Printer Friendly PDF Version 08/08/18 Summary ToggleTRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update Printer Friendly PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
